Navigation Links
Cholesterol-lowering drug shrinks enlarged prostates in hamster model
Date:10/21/2010

Boston, Mass. - A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

"We don't know the mechanism, but the results suggest to us that lowering cholesterol has the potential to reduce BPH in men," says senior author Keith Solomon, PhD, a biochemist, and member of the departments of Orthopaedic Surgery and Urology at Children's. "This brings up the possibility that other cholesterol lowering therapies, including exercise and diet, may prevent BPH from developing."

For unknown reasons, about half of men older than 50 (and 80 percent of men aged 80) develop BPH, most often evident as enlargement of the prostate. BPH leads to difficult urination, urgency, pain, and other symptoms that can cause significant reduction in the quality of life. In advanced stages, BPH can lead to renal failure. Standard medical and surgical treatments typically target the prostate and usually result in a reduction of symptoms but not without significant side effects in some men, Solomon said.

The study implicates circulating cholesterol in the progression of the condition and suggests a potential new strategy for prevention and treatment. The latest findings emerge from experiments with a strain of Syrian hamsters that undergo prostate enlargement naturally.

Led by first author Kristine Pelton, the team tested ezetimibe, an FDA-approved hypercholesterolemic drug (Zetia; Merck) against finasteride (Proscar, Propecia; Merck), a standard therapy for the treatment of BPH. Ezetimibe reduced prostatic enlargement in aged hamsters as effectively as finasteride and combining the two drugs worked better than either one alone.

In an unexpected finding, pathologist and co-author Dolores Di Vizio, MD, PhD, observed that finasteride caused atrophy of the hamster prostate while ezetimibe did not. "These findings provide strong evidence that the cholesterol-lowering drug inhibits BPH by a novel mechanism," said co-author Michael R. Freeman, PhD, professor of Surgery and director of urologic research at Children's Hospital.

The potentially therapeutic effect of cholesterol-lowering on enlarged prostates was pioneered 40 years earlier by co-author Carl Schaffner, PhD, professor emeritus at Rutgers University, who reported similar results in pre-clinical models using a different cholesterol-lowering drug.

"There is a lot more we want to do in the lab, with regards to studying BPH and the use of cholesterol-based therapies to control disease progression," says Solomon.

For example, the researchers want to test lower doses of ezetimibe and finasteride to examine whether the condition can be reversed with fewer side effects. They also want to assess prophylactic cholesterol lowering to determine if the enlargement can be prevented, and whether genes and proteins mediating the effect of cholesterol on the prostate can be identified. "We really want to be in the position to help conduct a clinical trial to test whether this therapy might have efficacy in human patients," Solomon said.

The study also validated the hamster strain as a good preclinical model for testing novel BPH therapies. "The preclinical models for BPH are few, require substantial manipulation or have an unpredictable disease course," Solomon says. "The Syrian hamster model that we are now using seems particularly good for examining the role of cholesterol in prostate disease, and the testing of novel drug therapies to help alleviate symptoms. We should be able to make substantial progress in developing new treatments and in understanding the molecular mechanisms underpinning the disease using these hamsters."


'/>"/>

Contact: Keri Stedman
keri.stedman@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
2. As girth grows, risk of sudden cardiac death shrinks
3. Drug for advanced kidney cancer shrinks tumors prior to surgery
4. Combination therapy more effective for enlarged prostate
5. Virginia Bioinformatics Institute to model immune responses to gut pathogens
6. New Medicare model guidelines for benefit years 2012-2014 in development
7. Disease transmission model says media coverage cuts infection rate and pandemic extent
8. New model may simplify high-dose radiosurgery planning
9. Treatment for S. aureus skin infection works in mouse model
10. Rheumatoid arthritis signaling protein reverses Alzheimers disease in mouse model
11. Scientists develop the first model for investigating the origins of testicular cancer in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... , ... September 03, 2020 , ... ... is sponsoring the American Foundation for Suicide Prevention’s (AFSP) annual signature event, Out ... people across hundreds of U.S. cities to raise awareness of suicide prevention. To ...
(Date:9/2/2020)... ... September 02, 2020 , ... RAM Technologies, Inc., the perennial ... and Special Needs plans, is proud to support the 2020 National Conferences on ... is supporting the event as a sponsor and exhibitor and will be showcasing ...
(Date:9/1/2020)... ... September 01, 2020 , ... Dr. Kiran ... in aesthetic surgery of the face, breast, and body. In 2018, she founded ... boutique plastic surgery and aesthetic practice in Southwest Florida. Dr. Gill and her ...
(Date:8/31/2020)... ... ... Want to get moving, break up your routine, and make a difference ... launch its fourth annual STEPtember campaign in the United States to raise funds and ... are at this moment — encouraging people to move in the ways that work ...
(Date:8/31/2020)... ... ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At this very turbulent ... panic, experiencing deep anxiety, immense stress, and right now are needing serious relief from a ... on the planet are experiencing a great degree of emotional discomfort, be it fear or ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... August 27, 2020 , ... Trella Health, the leading ... provider of cloud CRM, marketing automation, and contact center solutions for senior living ... integration of Trella’s performance intelligence data and insights into Enquire’s CRM solution to ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... Services, Laboratory Testing division, expands its technology footprint with the addition of ... platforms available. With industry-leading biomarker solutions, complemented with traditional ligand-binding assays and ...
(Date:8/26/2020)... ... , ... Hero Life Sciences announced today that it will be ... disposable face masks and N95 respirators in its manufacturing plant located in the City ... Americans are facing in trying to find quality disposable face masks during the COVID-19 ...
Breaking Medicine Technology: